Published in Medical Letter on the CDC and FDA, November 4th, 2007
Licensing of new drugs in Europe is increasingly controlled by the European Medicines Agency (EMEA), yet new drugs have only to show they are equivalent to current treatments rather than show superiority.
This favours the interests of drug companies, say Silvio Garattini and Vittorio Bertele from the Mario Negri Institute for Pharmacological Research in Italy. They believe that new drugs should be required to have some added value to current treatments or be cheaper.
One way to ensure this would be to introduce some...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA